


Searching News Database: PDUFA
HSMN NewsFeed - 28 Nov 2025
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
HSMN NewsFeed - 5 Mar 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
HSMN NewsFeed - 13 Apr 2020
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin(R) Gel 80 U/mL
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin(R) Gel 80 U/mL
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
HSMN NewsFeed - 26 Nov 2019
Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora(R) for the Prevention of Pregnancy
Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora(R) for the Prevention of Pregnancy
HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
HSMN NewsFeed - 22 Jul 2019
Vanda Pharmaceuticals FDA Update for HETLIOZ(R) in the Treatment of Jet Lag Disorder
Vanda Pharmaceuticals FDA Update for HETLIOZ(R) in the Treatment of Jet Lag Disorder
HSMN NewsFeed - 11 Mar 2019
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
HSMN NewsFeed - 29 Nov 2018
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis
FDA Accepts Filing of New Estrogen-free Oral Contraceptive Developed by Exeltis
HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
HSMN NewsFeed - 20 Apr 2018
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR(R)
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR(R)
HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
HSMN NewsFeed - 23 Feb 2018
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
HSMN NewsFeed - 10 Oct 2017
Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids
HSMN NewsFeed - 20 Jul 2017
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
Churchill Pharmaceuticals Announces NDA Filing Acceptance for YONSA(TM) by the U.S. FDA
HSMN NewsFeed - 19 Jul 2017
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
HSMN NewsFeed - 7 Apr 2017
Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer
Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
HSMN NewsFeed - 9 Jun 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
HSMN NewsFeed - 24 May 2016
Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
HSMN NewsFeed - 29 Mar 2016
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration
HSMN NewsFeed - 17 Mar 2016
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
Elite Announces U.S. FDA Priority Review Designation for SequestOx(TM) NDA
HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 19 Jan 2016
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
HSMN NewsFeed - 18 Nov 2015
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
HSMN NewsFeed - 15 Oct 2015
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
HSMN NewsFeed - 24 Aug 2015
Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs
HSMN NewsFeed - 15 May 2015
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
HSMN NewsFeed - 5 Aug 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
HSMN NewsFeed - 5 Jun 2014
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
HSMN NewsFeed - 25 Mar 2014
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
HSMN NewsFeed - 21 Jan 2014
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
HSMN NewsFeed - 30 Dec 2013
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
HSMN NewsFeed - 16 Dec 2013
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 13 Dec 2012
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
HSMN NewsFeed - 18 Oct 2012
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
HSMN NewsFeed - 13 Mar 2012
Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
Cornerstone Therapeutics Receives FDA Acceptance for CRTX 080 NDA for Treatment of Hyponatremia
HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvriâ„¢ and Plans to Resubmit in 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvriâ„¢ and Plans to Resubmit in 2012
HSMN NewsFeed - 14 Sep 2011
ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox(R) (deferiprone) Approval
ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox(R) (deferiprone) Approval
HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
HSMN NewsFeed - 11 Jul 2011
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
HSMN NewsFeed - 30 Jun 2011
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
HSMN NewsFeed - 17 Jun 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
HSMN NewsFeed - 22 Dec 2010
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
HSMN NewsFeed - 22 Jul 2010
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
HSMN NewsFeed - 1 Jul 2010
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
HSMN NewsFeed - 2 Mar 2010
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
HSMN NewsFeed - 1 Mar 2010
ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
HSMN NewsFeed - 20 Feb 2010
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
HSMN NewsFeed - 18 Jan 2010
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
HSMN NewsFeed - 10 Jun 2009
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
HSMN NewsFeed - 23 Apr 2009
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
HSMN NewsFeed - 25 Feb 2009
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer
HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
HSMN NewsFeed - 29 Jan 2009
FDA Accepts Eurand's Response to Approvable Letter for EUR-1008 as Complete
FDA Accepts Eurand's Response to Approvable Letter for EUR-1008 as Complete
HSMN NewsFeed - 9 Jan 2009
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
HSMN NewsFeed - 25 Sep 2008
Acusphere, Inc. Appoints Michael Slater SVP Regulatory Affairs and Operations Replacing Dennis Bucceri
Acusphere, Inc. Appoints Michael Slater SVP Regulatory Affairs and Operations Replacing Dennis Bucceri
HSMN NewsFeed - 4 Sep 2008
EPIX Pharmaceuticals To Regain Full Worldwide Commercial Rights For Vasovist(R)
EPIX Pharmaceuticals To Regain Full Worldwide Commercial Rights For Vasovist(R)
HSMN NewsFeed - 18 Aug 2008
Somaxon Pharmaceuticals Announces the Appointment of Senior Commercial Leadership
Somaxon Pharmaceuticals Announces the Appointment of Senior Commercial Leadership
HSMN NewsFeed - 7 Aug 2008
Somaxon Pharmaceuticals Appoints Richard W. Pascoe as President and Chief Executive Officer
Somaxon Pharmaceuticals Appoints Richard W. Pascoe as President and Chief Executive Officer
HSMN NewsFeed - 28 Jul 2008
Arpida Submits Marketing Authorisation Application for Intravenous Iclaprim in Europe
Arpida Submits Marketing Authorisation Application for Intravenous Iclaprim in Europe
HSMN NewsFeed - 30 Jun 2008
Acusphere Announces FDA Acceptance of Imagify(TM) NDA for Detection of Coronary Artery Disease
Acusphere Announces FDA Acceptance of Imagify(TM) NDA for Detection of Coronary Artery Disease
HSMN NewsFeed - 30 Jun 2008
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
HSMN NewsFeed - 31 Jan 2008
Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
Somaxon Pharmaceuticals Submits New Drug Application for SILENOR(TM) for the Treatment of Insomnia
HSMN NewsFeed - 14 Dec 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
HSMN NewsFeed - 20 Sep 2007
FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
HSMN NewsFeed - 28 Aug 2007
FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI
FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
HSMN NewsFeed - 22 May 2007
Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA
Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA
HSMN NewsFeed - 16 May 2007
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
HSMN NewsFeed - 23 Mar 2007
Advancis Pharmaceutical Resubmits New Drug Application for Once-Daily Amoxicillin PULSYS
Advancis Pharmaceutical Resubmits New Drug Application for Once-Daily Amoxicillin PULSYS
HSMN NewsFeed - 16 Mar 2007
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
HSMN NewsFeed - 14 Mar 2007
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products
HSMN NewsFeed - 14 Mar 2007
Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer In HIV/AIDS Diarrhea Assessment
Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer In HIV/AIDS Diarrhea Assessment
HSMN NewsFeed - 28 Feb 2007
Advancis Pharmaceutical Reaches Agreement with FDA for Resubmission of Amoxicillin PULSYS NDA
Advancis Pharmaceutical Reaches Agreement with FDA for Resubmission of Amoxicillin PULSYS NDA
HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
HSMN NewsFeed - 20 Dec 2006
Labopharm submits response to approvable letter for once-daily Tramadol to FDA
Labopharm submits response to approvable letter for once-daily Tramadol to FDA
HSMN NewsFeed - 13 Dec 2006
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
FDA Accepts New Drug Application for SANCTURA XR(TM) Submitted by Indevus
HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
HSMN NewsFeed - 10 Oct 2006
MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes
MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes
HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
HSMN NewsFeed - 26 Sep 2006
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
HSMN NewsFeed - 19 Sep 2006
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to-Moderate Atopic Dermatitis
Additional items found! 130
Members Archive contains
130 additional stories matching:
PDUFA
(Password required)
PDUFA
(Password required)
